image: Join us on March 22 in Paris & Online to learn more about the role of mitochondrial transplantation in enhancing outcomes for myocardial ischemia/reperfusion injury and its profound impact on the transcriptomic profile.
Credit: World Mitochondria Society (WMS)
Dr. James McCully of Harvard Medical School and Boston Children's Hospital, USA, invited by Dr. Marvin Edeas, from Institut Cochin, Université Paris Cité, France, will host an instructive discussion on Mitochondrial Transplantation.
This collaboration with the World Mitochondria Society (WMS) promises an insightful presentation by Dr. McCully on the topic of "Mitochondrial Transplantation: Rescue of Cellular Viability and Function and Modulation of the Ischemic Phenotype in the Myocardium." Dr. McCully will present the role of mitochondrial transplantation in enhancing outcomes for myocardial ischemia/reperfusion injury and its profound impact on the transcriptomic profile.
Marvin Edeas, chairman and founder of the WMS, Université Paris Cité, stated: “We invited Dr. James McCully as he plays a strategic role in the field of medicine, especially his groundbreaking work in pediatric cardiac surgery and his development of mitochondrial transplantation. Dr. McCully has dedicated his career to innovating treatment approaches for congenital heart conditions, significantly improving outcomes for pediatric patients. His research has not only advanced surgical procedures but also introduced new technologies to enhance the quality of life for children with heart defects.
The technique of mitochondrial transplantation, pioneered by Dr. McCully, represents a major advancement in medical science, offering a novel method to deliver healthy mitochondria directly to damaged tissues, thus rescuing organ function. This innovation, first applied at Boston Children's Hospital in 2014, has shown that mitochondrial transplantation can safely and effectively restore injured heart muscle, even in critical cases.
Given Dr. McCully's extensive publication record, with 234 papers and 13 patents, and his involvement in leading scientific associations, his expertise and contributions are highly valued by the medical community. His work aligns closely with the interests of the World Mitochondria Society, making him an ideal candidate to share insights on the therapeutic efficacy of mitochondrial transplantation in treating myocardial ischemia/reperfusion injury and its potential for broader applications in medicine.”
Date & Venue
The webinar is scheduled for Friday, March 22, 2024, from 3:00 PM to 5:15 PM Paris time.
Participants can choose to attend the event in two ways:
- In person at the Université Paris Cité, Institut Cochin - Bâtiment Méchain, Salle Rosalind Franklin, in Paris.
- Virtually, through a Zoom webinar.
Registration & Participation
Attendance at this webinar is free of charge, but space is limited. We encourage interested individuals to register early to secure their participation.
Registration link: https://cdn.jotfor.ms/240723340827453. The Zoom link will be sent after registration.
Mitochondrial Transplantation will be highlighted during WMS Annual Meeting
As an active member of the World Mitochondria Society’s scientific board, Dr. McCully 2024, he will be chairing a session during the Annual Targeting Mitochondria 2024 Congress “Mitochondrial Medicine 2024: From Bench to Bedside,” where mitochondrial transplantation will be prominently discussed.
About World Mitochondria Society
The World Mitochondria Society, established in 2010, is dedicated to addressing the evolving challenges in mitochondrial research with a forward-thinking agenda. Under the leadership of President Volkmar Weissig and Founder Marvin Edeas, we prioritize Emerging Trends and Strategies to stimulate innovative discussions and explore new avenues in mitochondrial science.
Where to Find WMS?